FDA Panel Recommends Expanded Use of CGMs
Insulin Nation
JULY 22, 2016
On July 21st, an FDA Advisory Committee panel convened to consider an application by Dexcom to relabel the G5 continuous glucose monitor (CGM) as a device suitable for use in making treatment decisions. Later that afternoon, the Diabetes Patient Advocacy Coalition broke the news on its Facebook page that the committee had voted for that labeling change.
Let's personalize your content